Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelavespib companion diagnostic - Samus Therapeutics

Next Previous
Drug Profile

Zelavespib companion diagnostic - Samus Therapeutics

Alternative Names: 124I-PU-H71; Iodine-124-PU-H71; Iodine-124-zelavespib; PU H71 companion diagnostic - Samus Therapeutics; PU H71 PET enhancer; PU H71 positron emission tomography enhancer

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Samus Therapeutics
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA (IV)
  • 31 Jul 2011 Samus Therapeutics obtains a licence to the patent covering PU H71 as a companion diagnostic
  • 01 Jul 2011 Memorial Sloan-Kettering Cancer Center initiates enrolment in a phase I trial for Cancer (Diagnosis) and Diagnostic imaging in USA (NCT01393509)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top